In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion

http://

Latest From Celltrion

Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA

Celltrion is seeking US approval for its subcutaneous formulation of infliximab, marketed in other territories as Remsima SC. The product will be registered as a standalone biologic rather than a biosimilar.

Biosimilars Review Pathway

At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023

With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.

Scrip Perspectives Generic Drugs

Keeping Track: Orphans Headline FDA Approvals; Gene Therapies Stand Out Among Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register